目的:评价控释前列腺素E2栓剂——普贝生促宫颈成熟及引产的有效性及安全性。方法:将256例单胎头位、宫颈Bishop评分≤5分、有阴道分娩适应证、无引产禁忌证的孕妇分为两组:156例给予普贝生一枚(10 mg)塞阴道促宫颈成熟作为研究组;100例给予催产素2.5 IU加入5%葡萄糖500 ml静脉微泵泵入作为对照组。对两组用药后宫缩、胎心、宫颈成熟度改变、用药至临产时间、破膜时间、胎儿娩出时间、羊水、剖宫产率及新生儿情况等进行观察。结果:研究组产妇给药后Bishop评分,148例提高≥2分,而对照组仅57例提高≥2分,两组比较,差异有统计学意义(P<0.05)。研究组从给药到分娩的时间为(1 290±978)分,对照组为(2 063±236)分,两组比较差异有统计学意义(P<0.05)。研究组的剖宫产率为27.0%,而对照组为67.0%。两组产妇产程中的胎心变化、羊水异常发生率无明显差异。两组新生儿出生时状况无明显差异。结论:普贝生是一种安全有效的促宫颈成熟及引产药物,对母婴无明显不良影响。 OBJECTIVE: To evaluate the efficacy and safety of controlled release prostaglandin E2 suppository-Probes for cervical ripening and induction of labor. Methods: Two hundred and sixty-six pregnant women with single fetal head and cervical Bishop score ≤5 were divided into two groups according to indications of vaginal delivery. 156 pregnant women were given pethidine one (10 mg) Mature as a research group; 100 patients given oxytocin 2.5 IU with 5% glucose 500 ml venous micropumps as a control group. After the treatment of two groups of contractions, fetal heart rate, changes in cervical maturity, medication to labor time, rupture time, fetal delivery time, amniotic fluid, cesarean section rate and neonatal conditions were observed. Results: In the study group, the Bishop score of maternal administration increased by ≥2 points in 148 cases, but increased by ≥2 points in 57 cases in control group. The difference was statistically significant (P <0.05). The time from administration to delivery was (1 290 ± 978) in the study group and (2 063 ± 236) in the control group, the difference was statistically significant (P <0.05). Cesarean section rate was 27.0% in the study group, compared with 67.0% in the control group. Fetal labor in the two groups of changes in fetal heart rate, amniotic fluid abnormalities no significant difference. There was no significant difference in the status of newborns at birth between the two groups. Conclusion: Pu Bei Sheng is a safe and effective cervical ripening and induction of drugs, no significant adverse effects on mother and child.